Neutralizing antibodies to interferon-beta may persist after cessation of therapy: What impact could they have?

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 245-246

  Polman, Chris H ^a   Killestein, Joep ^a   Schellekens, Huub ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BETA INTERFERON; BETA1A INTERFERON; ENDOTOXIN; INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANTIBODY PRODUCTION; ANTIBODY TITER; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CROSS REACTION; DENMARK; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; KNOCKOUT MOUSE; LONG TERM CARE; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT COMPLIANCE; SERUM SICKNESS; TREATMENT FAILURE; TREATMENT OUTCOME; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTRALIZATION TESTS;

EID: 33744782041     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1284ed     Document Type: Editorial

References (7)

1. Sorensen PS, Koch-Henriksen N, Ravnborg M, Frederiksen JL, Jensen K, Heltberg A et al on behalf of the Danish Multiple Sclerosis Study Group. Immuno-modulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006; 12: 253-264.
2. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al; Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
3. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS on behalf of The Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFN-β therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12: 247-252.
4. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
5. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res 2005; 22: 847-51.
6. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003; 170: 4776-84.
7. Erlandsson L, Blumenthal R, Eloranta ML, Engel H, Alm G, Weiss S et al. Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Curr Biol 1998; 8: 223-26.